Keith M. Kerr

Trial randomisation method (outlined in Chapter 2)

Stephen W. Duffy, David K. Whynes, John K Field, 2016 .

Data tables showing demographics of response and recruitment

Stephen W. Duffy, John K Field, David R Baldwin, 2016 .

Details of the Liverpool Lung Project risk model (version 2)

Stephen W. Duffy, David K. Whynes, John K Field, 2016 .

The Lungscape Project.

Keith M. Kerr, Lukas Bubendorf, Walter Weder, 2012 .

9002 ORAL Round Robin Test to Evaluate the Reproducibility of a Therapeutically Relevant Immunohistochemical Score for the Categorization of Non-Small Cell Lung Cancer (NSCLC) Into Tumours With High and Low Epidermal Growth Factor Receptor (EGFR) Expression

Keith M. Kerr, Reinhard Büttner, A. Von Heydebreck, 2011 .

Gene Expression Profiling in Non-Small Cell Lung Cancer

Keith M. Kerr, Graeme I. Murray, K. Kerr, 2004, Clinical Cancer Research.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

Ashwini Naik, Allan Hackshaw, Zoltan Szallasi, 2017, Nature.

Advances in Surgical Pathology: Lung Cancer

Keith M. Kerr, Timothy Craig Allen, Mary Beth Beasley, 2012 .

DNA Methylation Changes in Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, and Lung Adenocarcinoma

Kimberly D. Siegmund, Keith M. Kerr, Mihaela Campan, 2011, PloS one.

PL 03.03 Blueprint 2: PD-L1 Immunohistochemistry Comparability Study in Real-Life, Clinical Samples

Keith M. Kerr, F. Hirsch, Y. Yatabe, 2017 .

PD‐L1 Immunohistochemistry Comparability Study in Real‐Life Clinical Samples: Results of Blueprint Phase 2 Project

Hui Yu, Keith M. Kerr, Ignacio Wistuba, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.